Search

In academia as well as the intensely competitive pharmaceutical industry, it is critical to offer innovative hypotheses, methodologies and technologies that can shorten the drug research and development and provide higher success. In this article, we have demonstrated how innovative variations of scaffold hopping strategy have facilitated to successfully create new druggable molecular spaces, (1) drug to drug, clinical or preclinical candidates, (2) clinical candidates to clinical or preclinical candidates, and (3) bioactive agents to clinical candidates. This review also provides an analysis of molecular modulations that enabled improvement in the pharmacodynamics, physiochemical and pharmacokinetic properties (P3-properties). [Display omitted] • Molecular medicinal properties: Pharmacodynamics, physiochemical and pharmacokinetic properties (P3-properties). • Successful innovation: Drug to drug, Drug to clinical candidate, Clinical candidate to, clinical candidate, Clinical candidate to new agent, Bioactive agent to clinical candidate and Drug to new agent. • Advance synthetic methods: Molecular editing, insertion of functional motif, and an important innovative-path of drug discovery with rational integration of advance synthetic method and P3-properties. In both academia and the pharmaceutical industry, innovative hypotheses, methodologies and technologies that can shorten the drug research and development, leading to higher success rates, are vital. In this review, we demonstrate how innovative variations of the scaffold-hopping strategy have been used to create new druggable molecular spaces, drugs, clinical candidates, preclinical candidates, and bioactive agents. We also analyze molecular modulations that enabled improvements of the pharmacodynamic (PD), physiochemical, and pharmacokinetic (PK) properties (P3 properties) of the drugs resulting from these scaffold-hopping strategies. [ABSTRACT FROM AUTHOR]

[Display omitted] • "Nature-to-new" as a medicinal chemistry strategy. • Iterative Scaffold-hopping to identify new chemotype. • Organocatalysed Umpolung Chemistry to construct Arylidene heterocyclic-fused imidazolone scaffold. • Polyphosphoric acid-mediated ester-lactam exchange. • In silico study reveals good drug-like properties. A strategy of "Nature-to-new" with iterative scaffold-hopping was considered for investigation of privileged ring/functional motif-elaborated analogs of natural aurones. An organocatalyzed umpolung chemistry based method was established for molecular-diversity feasible synthesis of title class of chemotypes i.e. (Z)-2-Arylideneimidazo[1,2– a ]pyridinones and (Z)-2-Arylidenebenzo[ d ]imidazo[2,1–b]thiazol-3-ones. Various biophysical experiments indicated their important biological properties. The analogs showed characteristic anticancer activities with efficiency more than an anticancer drug. The compounds induced apoptosis with arrest in the S phase of the cell cycle regulation. The compounds' significant effect in up/down-regulation of various apoptotic proteins, an apoptosis cascade, and the inhibition of topoisomerases-mediated DNA relaxation process was identified. The analysis of the structure-activity relationship, interference with biological events and the drug-likeness physicochemical properties of the compounds in the acceptable window indicated distinctive medicinal molecule-to-properties of the investigated chemotypes. [ABSTRACT FROM AUTHOR]

[Display omitted] In this study of creating new molecules from clinical trial agents, an approach of Combretastatin structural modulation with the installation of NP-privileged motifs was considered, and a series of trimethoxyphenyl-2-aminoimidazole with functionalized quinolines and isoquinolines was investigated. An exciting method of quinoline C3-H iodination coupled with imidazopyridine-C3-H arylation and hydrazine-mediated fused-ring cleavage enabled synthesizing a class of compounds with two specific unsymmetric aryl substitutions. Interestingly, three compounds (6 , 11 , and 13) strongly inhibited HeLa cell proliferation with a half-maximal inhibitory concentration (10–46 nM). Among the compounds, compound 6 (QTMP) showed stronger antiproliferative ability than CA-4 (a clinical trial agent) in various cancer cell lines, including cervical, lung, breast, highly metastatic breast, and melanoma cells. QTMP inhibited the assembly of purified tubulin, depolymerized microtubules of A549 lung carcinoma cells, produced defective spindles, and arrested the cells in the G2/M phase. Further, QTMP binds to the colchicine site in tubulin with a dissociation constant of 5.0 ± 0.6 µM. QTMP displayed higher aqueous stability than CA-4 at 37 °C. Further, in silico analysis of QTMP indicated excellent drug-like properties, including good aqueous solubility, balanced hydrophilicity-lipophilicity, and high GI-absorption ability. The results together suggest that QTMP has anticancer potential. [ABSTRACT FROM AUTHOR]